Hait Biological Disclosure achieved revenue of 387 million yuan in the semi -annual report of 2022

On August 1, A -share listed company Hait Biological (Code: 300683.SZ) released the semi -annual performance report in 2022.

From January 1, 2022-June 30, 2022, the company realized operating income of 387 million yuan, an increase of 71.69%year-on-year, and net profit was 18.872 million yuan, an increase of 161.49%year-on-year, and the basic earnings per share were 0.15 yuan.

The company's industry is biological products.

During the company's reporting period, the total assets at the end of the period were 2.695 billion yuan, the operating profit was 26.7067 million yuan, the accounts receivable were 107 million yuan, and the net cash flow generated by operating activities was -28.468 million yuan.The cash is 311 million yuan.

Hait Biological, the company's full name Wuhan Hait Biopharmaceutical Co., Ltd., was established on April 08, 1992. The current general manager Chen Ya.Research and development, support for drug production and other related services.

- END -